Dr. Robert L. Parker JR., MD
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 276
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
NC license 27723
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Medicare patients and services
- Medicare patients, 2024
- 276
- Services billed
- 542
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Screening mammography | 297 | 297 |
| Screening 3d breast mammography | 279 | 279 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 17 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 7 companies reported 15 payments worth $1,651 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $1,528 |
|---|---|
| Astellas Pharma US Inc | $26.92 |
| Takeda Pharmaceuticals U.S.A., Inc. | $26.04 |
| Exeltis, USA Inc. | $22.21 |
| AbbVie Inc. | $17.21 |
| Shield Therapeutics Inc | $15.51 |
| Vertex Pharmaceuticals Incorporated | $14.81 |
| Travel and Lodging | $990 |
|---|---|
| Food and Beverage | $661 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Dec 9, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $748 |
| Bayer HealthCare Pharmaceuticals Inc. Dec 9, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $242 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 7 companies. The companies reported $98,611 in research payments for these studies, mostly to the institutions running them.
- Reference Range Study for the Quantra System with the QStat Cartridge in Obstetric Patients
Hemosonics LLC - Study name not reported
Roche Molecular Systems, Inc. - Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
Exeltis, USA Inc. · Completed · NCT05461573 - Study name not reported
Organon Llc - A phase 1 openlabel study to evaluate the pharmacokinetics safety and tolerability of orally administered nirmatrelvirritonavir in pregnant women with mildtomoderate COVID19
Pfizer Inc. - Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles
Mylan Inc. · Completed · NCT05139121 - An open-label, non-randomized, prospective observational cohort study to assess post-procedural outcomes in two cohorts of women who chose to undergo either hysteroscopic sterilization (Essure) or laparoscopic tubal s…
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.